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Abstract
Aims: The number of patients with cardiac implantable electronic devices (permanent pacemakers and implantable cardioverter deﬁbrillators) undergoing
radiotherapy treatment is increasing. The aims of this audit were to establish current UK practice regarding the management of patients with implanted cardiac
devices undergoing radiotherapy and to compare this practice with current ‘gold standard’ evidence-based guidelines.
Materials and methods: All UK radiotherapy departments were contacted and asked to provide their current cardiac implantable electronic device policy or to
indicate if there was no current policy. A proforma was created to analyse these polices and to compare with current best practice.
Results: In total, 47/67 (70%) radiotherapy departments responded and 45 departmental policies were submitted; 31/45 (69%) policies deﬁned the radiotherapy
tolerance dose to permanent pacemakers and 14/45 (31%) deﬁned the monitoring procedure for patients in line with current best practice. Only 5/45 (11%)
policies deﬁned the radiotherapy tolerance dose to implantable cardioverter deﬁbrillators and 12/45 (27%) deﬁned the monitoring procedure in line with
current best practice.
Conclusion: Most UK cardiac device policies do not reﬂect current best evidence. Policies are based on research carried out in 1994 by the American Association
of Physicists in Medicine. This evidence does not account for advances in cardiac implantable electronic device technology. Further research is urgently needed
to establish the effect of radiotherapy on these devices.
 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
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The life expectancy of the English and Welsh population
has increased bymore than 65% in the past century [1]. This
has resulted in a higher prevalence of cardiovascular
morbidity, leading to an increase in the number of patients
with cardiac implantable electronic devices (CIEDs) [2,3]. In
addition, the age-standardised incidence of cancer has
increased by more than 25% in the past 30 years [1]. It has
been estimated that 50e60% of all patients with cancer will
require radiotherapy during the course of their illness [4].
Therefore, with an ageing population and an increase in the
incidence of both cardiovascular morbidity and cancer, the
number of patients with CIEDs presenting for radiotherapy
treatment will probably increase [2,5,6].Author for correspondence: J. Lester, Velindre Cancer Centre, Velindre
Road, Whitchurch, Cardiff CF14 2TL, UK. Tel: þ44-292-0196159.
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http://dx.doi.org/10.1016/j.clon.2013.09.004There are two categories of CIED ﬁtted into patients;
permanent pacemakers and implantable cardioverter de-
ﬁbrillators (ICDs). Permanent pacemakers are referred to as
‘pacemakers’ in this paper. Pacemakers are permanent de-
vices and vary in sophistication. ICDs are more sophisti-
cated devices and have the ability to automatically
deﬁbrillate the heart by monitoring the patient’s heart rate
and delivering the appropriate electrical therapy.
Although most medical treatments pose little danger to
the functioning of CIEDs, radiotherapy has the potential to
cause device malfunction. Cardiac devices may be affected
in two ways; electromagnetic interference (EMI) and direct
damage to the circuitry via ionising radiation, both of which
may cause temporary and permanent device malfunction
[3]. Changes within the device parameters as result of EMI
are seen even when the CIED is placed outside the radio-
therapy treatment ﬁeld [7].
Over the past three decades, the design and technology
of CIEDs has evolved and the use of complementary metalier Ltd. All rights reserved.
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more sensitive to ionising radiation than bipolar semi-
conductor devices used previously, possibly resulting in
increased damage and catastrophic failure of the cardiac
conduction system in the device [9,10].
It is not possible to predict the exact behaviour of a CIED
when it is in or close to the radiotherapy treatment ﬁeld
[11]. In addition, published results are not consistent in
their ﬁndings or recommendations. Radiotherapy has been
shown to cause malfunction of CIEDs, ranging from inap-
propriate triggering, device reprogramming or device fail-
ure [12e14]. Other investigators have reported a minimal
effect of radiotherapy on CIEDs [15].
There is concern that the photon energy of the treatment
beam may also be important. Gelblum and Amols [16] dis-
cussed the possible effects of neutron contamination from
high-energy photon beams. They recommended the use of
low-energy beams (<10 MV), but there is little evidence to
support this recommendation.
The American Association of Physicists in Medicine
(AAPM) [17] published a report in 1994 on the safe use of
radiotherapy in patients with permanent pacemakers. The
AAPM report is the basis of most of the current CIED
departmental radiotherapy policies in the UK (authors’
observation). Frizzell [18] published a more contemporary
review and a distinction was made between pacemakers
and ICDs. Both the AAPM and the Frizzell reports are widely
referenced in the literature and in our opinion have the
most robust evidence base to support them. Despite this,
the AAPM report is now nearly two decades old and does
not reﬂect advances in CIED or radiotherapy technology.
However, in the absence of more contemporary evidence-
based guidelines on treating CIED patients with radio-
therapy, it is reasonable to compare current UK policies
with the AAPM recommendations, using the Frizzell update
to deﬁne current best practice for ICD management.
Below is a summary of the AAPM and Frizzell
recommendations:
AAPM Recommendations (pacemakers):
1. Pacemakers should not be placed in the direct
(unshielded) therapy beam.
2. The absorbed dose to be received by the pacemaker
shouldbeestimatedbefore treatment and limited to2Gy.
3. If the total estimated dose to the pacemaker might
exceed 2 Gy, pacemaker function should be checked
before radiotherapy and possibly at the start of each
following treatment week by a cardiologist.
4. Patients should be closely observed during the ﬁrst
radiotherapy treatment on a linear accelerator.
Frizzell Recommendations (ICDs):
1. The absorbed dose to be received by the ICD should
limited to 0.5 Gy.
2. Amagnet should be placed over an ICDwhen a patient is
exposed to radiation.
3. Notify all patients about the possibility of ICD mal-
function, failure or both.Monitoring recommendations:
1. Patients should be monitored with a continuous elec-
trocardiogram (ECG) strip during the ﬁrst radiotherapy
treatment. This strip should then be reviewed for any
evidence of pacing disruption when radiotherapy is
being administered.
2. ICD patients should undergo daily monitoring and staff
should document any changes in the patient’s physical
status and any changes in the ECG trace.
3. Monitoring should be carried out by fully trained and
competent health professionals. If therapeutic radiog-
raphers are monitoring patients, they should receive
speciﬁc training on the management and monitoring of
these patients.
4. If at any point malfunction is suspected or detected, the
clinical oncologist and cardiologist should be immedi-
ately informed.
Consent recommendations:
1. The patient is aware of potential adverse effects of
radiotherapy on CIEDs.
2. The patient is aware the ICD will be deactivated during
radiotherapy.
Currently, there are no UK or national guidelines on the
use of radiotherapy in patients with CIEDs and most
radiotherapy departments have no formal riskmanagement
strategy or policy in place [11]. The aims of this audit were
to establish current UK practice regarding the management
of patients with CIEDs undergoing radiotherapy and to
compare this practice with the current ‘gold standard’
AAPM and Frizzell recommendations.Materials and Methods
UK radiotherapy centres were identiﬁed using the Soci-
ety and College of Radiographers’ database. Between May
2012 and March 2013, all radiotherapy department man-
agers were e-mailed asking them to participate in a national
audit. Centres were asked to either provide their current
CIED policy or to indicate if there was no policy.
A proforma was created to analyse CIED policies
comprising two sections: ﬁrst, the roles and responsibilities
of healthcare professionals; second, treatment and man-
agement guidelines. All data collected were anonymised. A
database (Microsoft Excel) was created for the entry and
analysis of audit data and departmental guidelines were
compared. The results are presented as simple frequencies
and percentages.Results
In total, 67 radiotherapy centres were identiﬁed in the UK
and contacted. Overall, 47/67 (70%) departments responded
to the request to provide their policy for inclusion in the
audit. Forty-ﬁve departments provided their policy and two
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were excluded from the results. Twenty departments did
not respond to the request. The analysis was carried out on
the 45 polices submitted that are currently in use.
Table 1 summarises the roles and responsibilities of
healthcare professionals. Overall, 39/45 (87%) policies
require the clinical oncologist to state whether a CIED is
present on the radiotherapy referral form; 41/45 (91%)
policies require the clinical oncologist to contact the pa-
tient’s cardiology department before starting radiotherapy;
34/45 (76%) policies require a cardiology assessment; 36/45
(80%) policies require the clinical oncologist to provide
relevant information to medical physics to allow the
calculation of the estimated cumulative dose to the CIED
before starting radiotherapy; 12/45 (27%) policies require
patients ﬁtted with CIEDs to be informed of the risks to
themselves and their device before starting radiotherapy; 5/
45 (11%) policies state that patients ﬁtted with ICDs should
be informed about the possibility of ICD malfunction or
failure during radiotherapy and must give consent to
deactivate the ICD during radiotherapy.
Of note is that in only 29/45 (64%) policies is it mandatory
for the planning radiographer to contact the treating
consultant if theCIED iswithina radiotherapy treatmentﬁeld
or the estimated dose is too high. Less than a third of policies
include appropriate monitoring procedures for treatment
radiographers in patients with pacemakers or ICDs. There is
no requirement for medical physics to calculate the esti-
mated dose to CIEDs and leads in 9/45 (20%) policies.Table 1
Roles and responsibilities
Roles and responsibilities
Consultant oncologist
Identify patient’s CIED status and highlight on radiotherapy referral f
Contact patient’s cardiology department before starting radiotherapy
Request cardiology assessment
Provide medical physics with information to calculate cumulative rad
Dose to the implantable internal pacemaker does not exceed 2 Gy
Dose to the ICD does not exceed 2 Gy
Consent e patient aware of potential adverse effects of radiotherapy
Consent e switch off ICD during radiotherapy
Planning radiographers
Annotated patient’s CIED status
CIED included in scan if in/close to the radiotherapy treatment ﬁeld
Medical physics informed of patient’s CIED status
Contact consultant if CIED is within radiotherapy treatment ﬁeld or e
Treatment radiographers
Appropriate monitoring procedure for patients with pacemakers
Appropriate monitoring procedure for patients with ICDs
Medical physics
Dose estimation calculated for CIEDs and leads
CIED, cardiac implantable electronic device; ICD, implantable cardioveTable 2 summarises adherence to current guidelines: 31/
45 (69%) policies deﬁne the radiotherapy tolerance dose to
the pacemaker recommended in the AAPM guidelines. Of
these, 21/31 (68%) policies require the cardiology depart-
ment to be contacted to discuss safe management of the
patient. In total, 14/45 (31%) policies do not deﬁne a toler-
ance dose limit to the pacemaker and none of these radio-
therapy departments contact the patient’s cardiology
department. Only 5/45 (11%) policies deﬁne the radio-
therapy tolerance dose limit to the ICD as 0.5 Gy and all ﬁve
of these radiotherapy departments contact the cardiology
department to discuss the management of the patient; 23/
45 (51%) policies deﬁne a dose limit of >0.5 Gy to the ICD
and 17/45 (38%) policies do not deﬁne a dose limit. 39/40
(98%) policies that use an incorrect tolerance dose limit or
do not deﬁne a dose limit do not mandate contacting the
patient’s cardiology department for advice. 30/45 (67%)
policies require a follow-up appointment to be made with
the patient’s cardiology department after the completion of
radiotherapy.
Table 3 summarises the monitoring requirements for
patients with CIEDs receiving radiotherapy. Overall, 31/45
(69%) policies do not deﬁne monitoring procedures for pa-
tients with pacemakers in line with the AAPM guidelines
and none mandate the use of appropriately trained staff to
monitor patients. Similarly, 33/45 (73%) policies do not
deﬁne monitoring procedures for patients with ICDs in line
with the Frizzell report and none mandate the use of
appropriately trained staff to monitor patients.Results (n ¼ 45 unless stated
otherwise)
Number of radiotherapy
department policies
%
orm 39 87
treatment 41 91
34 76
iotherapy dose to CIED 36 80
31 69
5 11
on cardiac device 12 27
5 11
34 76
35 78
35 78
stimated dose too high 29 64
14 31
12 27
36 80
rter deﬁbrillator.
Table 2
Adherence to American Association of Physicists in Medicine (AAPM) and Frizzell guidelines
Guidelines Results (n ¼ 45 unless stated
otherwise)
Number of radiotherapy
department policies
%
Pacemakers e AAPM guidelines
2 Gy radiotherapy tolerance dose to device stated 31 69
Requirement to contact cardiology if radiotherapy dose to pacemaker exceeds 2 Gy 21 (of 31) 68
No radiotherapy tolerance dose stated 14 31
Do not contact cardiology 14 (of 14) 100
Cardiology follow-up made after radiotherapy completed 30 67
ICDs e Frizzell Report
0.5 Gy radiotherapy tolerance dose to device stated 5 11
Requirement to contact cardiology if radiotherapy dose to ICD exceeds 0.5 Gy 5 (of 5) 100
1 Gy radiotherapy tolerance dose to device stated (exceeding 0.5 Gy tolerance dose) 9 20
Do not contact cardiology if radiotherapy dose to ICD exceeds 1 Gy 9 (of 9) 100
2 Gy radiotherapy tolerance dose to device stated (exceeding 0.5 Gy tolerance dose) 14 31
Do not contact cardiology if radiotherapy dose to ICD exceeds 2 Gy 13 (of 14) 93
No radiotherapy tolerance dose stated 17 38
Do not contact cardiology if no radiotherapy tolerance dose is stated 17 (of 17) 100
Cardiology follow-up made after radiotherapy completed 30 67
ICD, implantable cardioverter deﬁbrillator.
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The number of patients with CIEDs undergoing radio-
therapy treatment is increasing [2,5,6]. There is limited
published research on the effect of radiotherapy on CIEDs,
but there is evidence to show radiotherapy at low doses can
cause malfunction or failure with potentially life-
threatening consequences [10]. Given this risk, all radio-
therapy centres should have policies in place to support the
safe radiotherapy treatment of patients with CIEDs.
This audit used the AAPM guidelines and Frizzell report
as the benchmark to compare UK radiotherapy de-
partments’ current CIED policies, as in the opinion of the
authors, these guidelines had the most robust evidence
base to support them [17,18].Table 3
Monitoring
Clinical practice e monitoring of patients with cardiac devices
Pacemakers e AAPM guidelines
Appropriate monitoring procedure
Appropriate staff used to monitor patients
Close observation of patient using cardiac monitor on ﬁrst fraction of
Subsequent monitoring requirements assessed and annotated
ICDs e Frizzell report
Appropriate monitoring procedure
Appropriate staff used to monitor patients
12 lead continuous strip ECG before ﬁrst fraction of radiotherapy
Deactivate ICD with magnet during radiotherapy
Continuous strip ECG monitoring for all subsequent treatments
Document any change in patient’s status
AAPM, American Association of Physicists in Medicine; ECG, electrocarThe ﬁrst question we wanted to answer was how many
UK radiotherapy centres have a CIED policy in routine use.
All radiotherapy department managers were asked to pro-
vide their current policy for analysis. The request yielded a
response rate of 70%; 45 respondents provided their policy
and two centres stated that they are currently re-writing
their policy. A third follow-up e-mail has been sent from
the Society of Radiographers on behalf of the researchers
asking radiotherapy departments to forward their policy or
to inform the researchers if they do not have one. This will
allow a more detailed national picture to be established in
the future, but a response rate of 70% was felt high enough
to proceed with this review. At this point, it is not known
whether the remaining 20 radiotherapy departments who
have not responded have a policy, but it is possible that upResults (n ¼ 45 unless stated
otherwise)
Number of radiotherapy
department policies
%
14 31
14 31
radiotherapy 14 31
14 31
12 27
12 27
12 27
12 27
12 27
12 27
diogram; ICD, implantable cardioverter deﬁbrillator.
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aging patients with CIEDs. Given the potential risk from
radiotherapy to patients with CIEDs, it is concerning that a
signiﬁcant proportion may not have a policy to guide
healthcare professionals. The lack of an over-arching na-
tional policy on this therapy area is not speciﬁc to the UK.
An American report suggests that 12% of US oncology de-
partments have neither a formal risk management strategy
nor a cardiac device policy and that only 15% have a written
policy [11].
The audit results highlight signiﬁcant differences be-
tween policies in the roles and responsibilities of healthcare
professionals involved in the patient pathway and the
management of patients with a CIED receiving radio-
therapy. From the results of the audit, in 87% of radio-
therapy departments the treating clinical oncologist
determines CIED status and highlights it on the radio-
therapy referral form. This means that in 13% of the policies
included in this review, it is left to radiographers to identify
whether a CIED is present. Anecdotal evidence from this
audit shows that in some cases, a CIED is not discovered
until a patient attends for radiotherapy. This results in
treatment being delayed or treatment proceeding without
safety measures in place. It is not known howmany patients
with CIEDs undergo radiotherapy without the knowledge of
the therapeutic radiographers, but this potentially
dangerous scenario is less likely if the treating oncologist
determines early on in the treatment pathway that a device
is present and informs the planning and treatment teams.
Worryingly, in only 29/45 (64%) policies is it mandatory for
the treating consultant to be contacted if the CIED is within
a radiotherapy treatment ﬁeld or the estimated dose is too
high. In most cases, this communication would probably
happen even in the absence of policy. However, given the
potential harm to the patient, this should be explicit. There
is clearly a need for policies in use to include monitoring
procedures for treatment radiographers in patients with
pacemakers or ICDs. These procedures are currently
included in less than one-third of policies and it is vital that
patients having treatment are monitored to minimise the
chance of harm. There is no requirement formedical physics
to calculate the estimated dose to CIEDs and leads in 9/45
(20%) policies. Without this estimation being made before
radiotherapy starts, patients may be exposed to doses of
radiation that exceed the limits recommended by AAPM
and Frizzell.
Patients consenting for any type of treatment need to be
informed of potentially serious side-effects related to that
treatment. Nearly three-quarters of policies do not mandate
discussion of potential damage to the CIED during and after
radiotherapy in the treatment consent process. Given the
lack of contemporary research in this area, it is not possible
to quantify this risk of damage or harm at present, but
consideration should be given to discussing potential
complications in all patients with a CIED. ICDs are probably
susceptible to radiotherapy damage at lower doses than
pacemakers and ICD patients should be informed about the
possibility of malfunction or failure during radiotherapy
treatment as the consequences may be devastating. ICDpatients also need to be told in advance of radiotherapy that
their device will be deactivated using a magnet during
treatment.
The AAPM report recommended that the cumulative
radiotherapy dose to the pacemaker be limited to less than
2 Gy [17]. In the audit, only 31/45 (69%) radiotherapy de-
partments limit the cumulative dose to the pacemaker to
2 Gy and of these, only 21/31 (68%) require communication
with the cardiology department if the dose exceeds 2 Gy. It
is concerning that nearly a third of policies deﬁne no
tolerance dose to the pacemaker. There is evidence that
even low cumulative doses of radiotherapy may damage
CIEDs and patients are probably being put at risk of harm
with the current policies in use.
The Frizzell report recommended a lower radiotherapy
tolerance dose of 0.5 Gy for ICDs and that they should be
deactivated before radiotherapy by placing a magnet over
the device to prevent inappropriate therapy or shock de-
livery as a result of accidental sensing of EMI interference
[18]. Worryingly, the audit shows that only 5/45 (11%)
radiotherapy departments limit the ICD dose to 0.5 Gy, 23/
45 (51%) radiotherapy departments specify a higher ICD
tolerance than recommended and 17/45 (38%) do not state a
radiotherapy tolerance dose. That means that in most cen-
tres with a cardiac device policy, ICDs are potentially
exposed to doses of radiotherapy that may affect function
and cause serious harm to the patient.
In addition, it is of signiﬁcant concern that only 6/45
(13%) CIED policies differentiate between pacemakers and
ICDs and subsequently apply radiotherapy tolerance dose
limits to both types of device. In these policies, ICDs are
subject to the same radiotherapy tolerance dose limits and
the samemonitoring procedures as pacemakers. As a result,
ICDs are almost certainly being subjected to radiotherapy
doses beyond tolerance and ICDmalfunction has potentially
life-threatening consequences.
The AAPM and Frizzell reports recommend that all pa-
tients with CIEDs be monitored with a continuous ECG strip
during their ﬁrst radiotherapy treatment for any evidence of
pacing disruption [17,18]. In addition, they should be
monitored by an appropriately trained health professional.
The audit shows that over two-thirds of policies do not
mandate the monitoring procedures deﬁned by AAPM and
Frizzell and less than one-third require the use of an
appropriately trained health professional to carry out the
monitoring. Therefore, a signiﬁcant number of patients with
CIEDs are undergoing radiotherapy with no monitoring and
in those that are monitored most of the staff involved may
not have appropriate training to interpret ECG or clinical
changes.Conclusion
This audit of CIED policies is based on a 70% response rate
from radiotherapy centres in the UK. It cannot be deﬁnitive
in its conclusions, but important themes have emerged
nevertheless. It is clear that policies differ between radio-
therapy centres. In addition, a signiﬁcant proportion of
J.F. Lester et al. / Clinical Oncology 26 (2014) 45e5050policies do not adhere to current established tolerance
doses for CIEDs. As a consequence, it is very likely that pa-
tients are being put at signiﬁcant risk of harm. We are car-
rying out urgently needed research to further deﬁne the
effect of radiotherapy on modern cardiac devices. This
research will underpin the development of contemporary
evidence-based guidelines on the use of radiotherapy in
patients with these devices.
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